CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $28.36M, lower than 95% of all stocks globally
- PositionReturn on equity is -1021.1%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
893.48MEUR1.04B · vs all stocks (USD)
Revenue (TTM)
24.28MEUR28.36M · vs all stocks (USD)
Profit Margin
-128.88%vs Biotechnology peers
Beta
0.9780xvs all stocks
52-Week Change
43.81%vs all stocks
Market Capitalization
893.48MEUR1.04B · vs all stocks (USD)
Enterprise Value
853.28MEUR996.85M · vs all stocks (USD)
Forward P/E
59.24xvs Biotechnology peers
Price to Sales (TTM)
36.80xvs Biotechnology peers
Price to Book (MRQ)
292.71xvs Biotechnology peers
Enterprise to Revenue
35.15xvs Biotechnology peers
Enterprise to EBITDA
-42.58xvs Biotechnology peers
Profit Margin
-128.88%vs Biotechnology peers
Operating Margin
-139.50%vs Biotechnology peers
Return on Assets (TTM)
-13.06%vs Biotechnology peers
Return on Equity (TTM)
-1021.12%vs Biotechnology peers
Revenue (TTM)
24.28MEUR28.36M · vs all stocks (USD)
Revenue per Share (TTM)
0.7280EURUpdated Aug 21, 2026Quarterly Revenue Growth
-44.60%vs Biotechnology peers
Gross Profit (TTM)
24.28MEUR28.36M · vs all stocks (USD)
EBITDA (TTM)
-20.04MEUR-23.41M · vs all stocks (USD)
Net Income (TTM)
-31.29MEUR-36.55M · vs all stocks (USD)
Operating Cash Flow (TTM)
-24.55MEUR-28.69M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-19.78MEUR-23.11M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00EURFY2025 · Mar 31, 2025Revenue
25.54MEURFY2025 · Mar 31, 2025Cost of Goods Sold
0.00EURFY2025 · Mar 31, 2025Gross Profit
25.54MEURFY2025 · Mar 31, 2025Operating Income
-10.84MEUR-12.66M · vs all stocks (USD)
Pre-tax Income
-18.28MEURFY2025 · Mar 31, 2025Income Tax Expense
160.00KEURFY2025 · Mar 31, 2025Net Income
-18.44MEURFY2025 · Mar 31, 2025EBIT
-13.19MEURFY2025 · Mar 31, 2025EBITDA (Income Statement)
-11.20MEURFY2025 · Mar 31, 2025Research & Development
24.31MEURFY2025 · Mar 31, 2025Selling, General & Administrative
529.00KEURFY2025 · Mar 31, 2025Other Operating Expenses
3.84MEURFY2025 · Mar 31, 2025Non-operating Interest Income
0.00EURFY2025 · Mar 31, 2025Non-operating Interest Expense
5.09MEURFY2025 · Mar 31, 2025EPS (Basic)
-0.6200EURFY2025 · Mar 31, 2025EPS (Diluted)
-0.6200EURFY2025 · Mar 31, 2025Basic Shares Outstanding
29.64MSharesFY2025 · Mar 31, 2025Diluted Shares Outstanding
29.64MSharesFY2025 · Mar 31, 2025Net Income from Continuing Operations
-18.44MEURFY2025 · Mar 31, 2025Minority Interests (P&L)
0.00EURFY2025 · Mar 31, 2025Preferred Stock Dividends
0.00EURFY2025 · Mar 31, 2025Operating Cash Flow
14.12MEURFY2025 · Mar 31, 2025Free Cash Flow
13.37MEURFY2025 · Mar 31, 2025Cash & Cash Equivalents (End of Period)
59.04MEURFY2025 · Mar 31, 2025Starting Profit (CF Statement)
-18.44MEURFY2025 · Mar 31, 2025Stock-based Compensation
2.96MEURFY2025 · Mar 31, 2025Other Non-cash Items
7.21MEURFY2025 · Mar 31, 2025Change in Accounts Receivable (CF)
-937.00KEURFY2025 · Mar 31, 2025Change in Other Assets/Liabilities
23.32MEURFY2025 · Mar 31, 2025Capital Expenditures
-747.00KEURFY2025 · Mar 31, 2025Net Intangibles (CF)
-913.00KEURFY2025 · Mar 31, 2025Net Investing Cash Flow
-747.00KEURFY2025 · Mar 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Mar 31, 2025Long-term Debt Payments
-4.11MEURFY2025 · Mar 31, 2025Net Financing Cash Flow
35.73MEURFY2025 · Mar 31, 2025Shares Outstanding
35.91MSharesUpdated Aug 21, 2026Float Shares
32.79MSharesUpdated Aug 21, 2026% Held by Insiders
33.99%vs all stocks
% Held by Institutions
31.75%vs all stocks
Total Cash (MRQ)
84.82MEUR99.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.36EURUpdated Aug 21, 2026Total Debt (MRQ)
71.92MEUR84.02M · vs all stocks (USD)
Total Debt to Equity (MRQ)
23.47xvs Biotechnology peers
Current Ratio (MRQ)
4.67xvs Biotechnology peers
Book Value per Share (MRQ)
0.0850EURUpdated Aug 21, 2026Total Assets
90.45MEUR105.67M · vs all stocks (USD)
Total Current Assets
80.62MEURFY2025 · Mar 31, 2025Total Liabilities
106.82MEURFY2025 · Mar 31, 2025Total Non-current Assets
9.84MEURFY2025 · Mar 31, 2025Total Non-current Liabilities
76.94MEURFY2025 · Mar 31, 2025Total Current Liabilities
29.87MEURFY2025 · Mar 31, 2025Cash
59.04MEURFY2025 · Mar 31, 2025Cash & Cash Equivalents
59.04MEURFY2025 · Mar 31, 2025Other Short-term Investments
12.86MEURFY2025 · Mar 31, 2025Accounts Receivable
1.42MEURFY2025 · Mar 31, 2025Accounts Payable
4.00MEURFY2025 · Mar 31, 2025Short-term Debt
7.29MEURFY2025 · Mar 31, 2025Other Current Liabilities
134.00KEURFY2025 · Mar 31, 2025Long-term Debt
51.46MEURFY2025 · Mar 31, 2025Other Non-current Liabilities
13.69MEURFY2025 · Mar 31, 2025Common Stock (Book)
331.00KEURFY2025 · Mar 31, 2025Retained Earnings
-18.44MEURFY2025 · Mar 31, 2025Total Shareholders' Equity
-16.37MEUR-19.12M · vs all stocks (USD)
52-Week Low
16.64EURUpdated Aug 21, 202652-Week High
39.68EURUpdated Aug 21, 202652-Week Change
43.81%vs all stocks
Beta
0.9780xvs all stocks
50-Day MA
26.03EURUpdated Aug 21, 2026200-Day MA
25.45EURUpdated Aug 21, 2026Avg 10-Day Volume
45.02KSharesUpdated Aug 21, 2026Avg 30-Day Volume
59.49KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.9400EURUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -1021.1%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -10.21Industry median: -0.22Industry P5: -1.66Peers compared: 261
Debt-to-equity is 23.47×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 23.47Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 292.71×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 292.706Industry median: 2.97Industry P95: 23.50Peers compared: 261
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 36.80Revenue Growth YoY: -0.45
Significant cash reserves alongside high leverageNotable
Cash (USD): 99,092,981.46Total Debt (USD): 84,015,417.9Debt-to-Equity: 23.47
Financial Health
Consistent revenue growth patternNotable
Growth Consistency Score: 0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $28.36M, lower than 95% of all stocks globallySignificant
Revenue (USD): 28,361,848.02Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Animal Husbandry Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Haohai Biological Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Protagonist Therapeutics Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Delcath Systems Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Spire Global Inc.
2 interpretationsCash-Flow Ratios ElevatedHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC